When a gene therapy company needed to verify plasmid identity, purity, and integrity for an IND submission, Avance Biosciences delivered a validated NGS-based solution. The assay enabled low-level variant detection and trace contaminant analysis, supporting FDA compliance and lot release.
Avance Biosciences is proud to announce the partial commissioning of our new GMP facility at 5500 Northwest Central Drive in Houston, Texas. Effective July 21, 2025, select Biologics Quality Control services, including Microbiology and Sanger sequencing, will transition from our West Little York site to this new location. Please begin shipping samples directly to the new facility as we continue to expand our capabilities to better serve our clients.
Our new blog series explore how cutting-edge NGS technologies are being applied to solve real-world challenges in biopharmaceutical development. Follow along for insights into assay strategies, platform selection, and the measurable impact of our scientific approach...
Avance Biosciences now offers LC-MS/MS services to support precise bioanalytical testing for small molecules, peptides, oligonucleotides, and biomarkers, enhancing drug development with advanced PK/PD, impurity profiling, and targeted proteomics capabilities...
Avance Biosciences™ is proud to announce its participation in the Bioprocessing Summit 2025 in Boston, MA. Visit Booth #516 to learn how our GLP- and GMP-compliant analytical services support the development and manufacturing of biologics, cell and gene therapies, and advanced biotherapeutics...
Our existing 28,000 sq. ft. of lab space is expanding by an additional 17,000 sq. ft., enhancing our GLP, GMP and CLIA testing capabilities...
Avance delivers end-to-end NGS workflow compliance with a robust framework for data integrity, pipeline validation, and audit readiness—tailored for regulated environments...
An NIH-supported team has delivered the first personalized CRISPR-based gene therapy to an infant with CPS1 deficiency, offering new hope for rare disease treatment. The customized approach shows early success and may pave the way for future individualized therapies...
The FDA is embracing AI to streamline drug reviews, aiming for full implementation by June 2025. Following a successful pilot, this move could fast-track therapy approvals and reduce administrative tasks for scientists...
Verve Therapeutics’ VERVE-102 shows early success in lowering LDL cholesterol by 55% with a single dose, offering a potential one-time gene editing treatment for familial hypercholesterolemia...
